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The nuclear phosphoprotein p53 was first identified on co-
precipitation with SV40 large T antigen from SV40 infected
murine cells (Lane & Crawford, 1979; Linzer & Levine,
1979), the first observed interaction between a host cell pro-
tein and a viral oncogene (Lane & Benchimol, 1990). Normal
p53 is found at low levels in virtually all mammalian cells
(Rogel et al., 1985) and various studies have shown elevated
levels of the mRNA and protein in a wide variety of tumours
and tumour cell lines (Linzer & Levine, 1979; De Leo et al.,
1979; Crawford et al., 1981; Benchimol et al., 1982; Rotter,
1983; Thomas et al., 1983) including breast cancer (Cattoretti
et al., 1988; Thompson et al., 1990). The normal function of
p53 is not known, but it is thought to be involved in the
GO/GI to S transition in the cell cycle (Mercer et al., 1984;
Ganon & Lane, 1987) where regulation of its activity may be
through phosphorylation. Evidence suggests that p53 may
behave as a negative regulator, that it is essential for normal
growth and that its inactivation may be necessary for the
development of malignancy (Lane & Benchimol, 1990).
p53 was initially thought to behave like an oncogene in
that it transformed normal rat fibroblasts when co-trans-
fected with activated Ha-ras (Eliyahu et al., 1984; Jenkins et
al., 1984; Parada et al., 1984). Subsequently this was shown
to be true only for mutant p53 and not for the normal
product of the wild-type allele (Eliyahu et al., 1988; Hinds et
al., 1989). In fact, the normal allele, when co-transfected with
activated ras plus mutant p53, behaves as a tumour suppres-
sor (Finlay et al., 1989). Tumour suppressor genes behave in
a recessive way so that inactivation or loss of both alleles is
required for tumour progression to occur (Knudson, 1971;
Stanbridge, 1976). Loss of heterozygosity (LOH) studies have
implicated a number of chromosomal sites consistently lost in
the development of particular tumours (Ponder, 1988). Hemi-
zygosity for chromosome 17pl3.1, a region in which the
human p53 gene is located (Isobe et al., 1986), was shown to
occur in a high proportion of colorectal carcinomas (Vogel-
stein et al., 1989) and, based on the hypothesis that p53
might behave as a tumour suppressor gene, mutations were
looked for and found in the remaining allele of two such
patients (Baker et al., 1989). Subsequently mutations in p53
have been found in a number of tumours or tumour cell lines
where LOH for 17p has been reported (Nigro et al., 1989),
including a recent study by our own group on sporadic
breast tumours (Prosser et al., 1990). In our own studies, in
which our search for mutations was restricted to part of the
p53 gene, we found that eight out of 60 tumours contained a
mutation in exons five or six and estimated that these find-
ings reflected the presence of a p53 mutation in some 30% of
all sporadic breast tumours.
More than 60% of breast cancer patients show LOH for
markers in the 17p region (Mackay et al., 1988; Devilee et
al., 1989; Thompson et al., 1990). This high figure, together
with our evidence that p53 may behave as a tumour suppres-
sor gene in sporadic breast tumours, led us to ask if a
mutation in one allele of the p53 gene could be an inherited
predisposing component in families showing a high incidence
of breast cancer. We therefore analysed constitutional DNA
from two affected individuals from each of five extended
pedigrees showing this trait (Figure 1). These families may
represent genetically distinct categories of 'familial breast
cancer', depending on the presence of an excess of other
malignancies. DNA from blood, or from blood-derived lym-
phoblastoid cell lines, from these ten patients was examined
for mutations in the p53 gene. The same amplification mis-
match technique (Montandon et al., 1989; Cotton et al.,
1988) used in our previous study was applied, but on this
occasion all 11 exons of the gene were PCR amplified in
seven segments (Figure 2) and all segments were tested by
hydroxylamine and osmium tetroxide modification, followed
by piperidine cleavage (Figure 3). Using the oligos listed in
Figure 2 we would expected to find mutations in the p53
exons and in the splice junctions of the introns (with the
exception of the splice junction 5' to exon 2 and the first five
nucleotides of that exon). As long as the gene is correctly
spliced, it is possible that intron mutations could be toler-
ated, but to date there is no evidence about this with regard
to the p53 gene. In the literature, mutations in p53 associated
with particular tumours have been reported exclusively in
exons (Nigro et al., 1989; Prosser et al., 1990 and references
therein). In the ten individuals included in this study no
mutations were found in the p53 genes as covered by the
oligos used. We conclude that in these five families structural
abnormalities of the p53 gene do not contribute to the
inherited propensity to develop breast cancer. It should also
be noted that none of the eight breast cancer patients in
whose tumours we had detected p53 mutations gave a posi-
tive family history of the disease (Prosser et al., 1990).
Evidence from this laboratory (Coles et al. 1990) implicates
two independent regions of LOH on chromosome 17p in
breast tumours; one encompasses the p53 gene, but the more
common one is some 20 megabases telomeric to it. It remains
possible, therefore, that a mutation in another tumour sup-
pressor gene on 17p is involved in heritable breast tumours.
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Figure I Pedigrees of five families showing a high incidence of breast cancer. In almost all cases, the disease presented before age
50. O, Female; O, Male; *, Breast cancer; *Br', Bilateral breast cancer; *OvBr, Breast and ovarian cancer; 3 0N, Other cancer:
C = colon, OV = ovarian, CX =cervix, Oes = oesophagus, Sa= sarcoma, P =prostate, Sk=multiple basal cell skin cancers,
L = lung, NF = Neurofibrosarcoma, CNS = Astrocytoma, U =uterus, NE =Neuropithelioma. Arrows indicate the two patients
from each kindred from whom DNA was analysed.
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Figure 2 The I11 exons of the pS3 gene were PCR amplified in 7
segments. The oligos for each segment are as follows:
1-1 5'GGA TTC CTC CAA AAT GAT TT3'
1-2 5'TCA GTC AGG AGC TTA CCC AA3'
11-1 5'AGA CTG CCT TCC GGG TCA CT3'
11-2 5'GCA ACT GAC CGT GCA AGT CA3'
111-1 5'TTC CTC TTC CTG CAG TAC TC3'
III1-2 5'AGT TGC AAA CCA GAC CTC AG3'
IV-1 5'GTG TTG TCT CCT AGG TTG GC3'
IV-2 5'AGA CTT AGT ACC TGA AGG GT3'
V-1 5'CTC TGT TGC TGC AGA TCC GT3'
V-2 5'GCT GAG GTC AGT GAG GTG GA3'
VI-l 5'CAC CTG AAG TCC AAA AAG GG3'
VI-2 5'CAA GAC TTG ACA ACT CCC TC3'
VII-I 5'ACA GTT GGG CAG CTG GTT AG3'
VII-2 5'GTG GCA GCA AAG TTT TAT TG3'
Sequence information and the diagram above are from Buchman
el al. (1988). NB Several of the introns between segments are very
large and are not shown to scale.
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Figure 3 Two examples of results from the amplification mismatch technique in which the affected individuals are lettered A-H,
V and W. a, Segment III using hydroxylamine (HA), b, segment III using osmium tetroxide (OS04). The positive control ( x 2) in a
is a tumour mutation in p53 segments III (32T). The positive control in b is and al antitrypsin mutation in which the two
heteroduplexes contain respectively a C and a T mismatch and both are visible. The negative control is (l antitrypsin homoduplex.
The technique for HA modification is as described in Prosser et al. (1990). For OS04 modification, essentially the same procedure
was followed except that the heteroduplex was taken up in 61t ITE, 2.5 tlI of 10 x buffer (100mM Tris pH 7.7, 10mM EDTA, 15%
pyridine) was added and 15 fLI of freshly diluted OS04 (one-tenth dilution of 8% solution). This was incubated at 37°C for 10 min
and then precipitated before proceeding as described for HA modification. Segment V was cleaned using MERmaid (Stratech
Scientific Ltd).
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